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Host–Pathogen Interactions: A Biological
Rendez-Vous of the Infectious Nonself
and Danger Models?
Jean-Nicolas Tournier*, Anne Quesnel-Hellmann
‘‘Les phe ´nome `nes biologiques pre ´sentent une telle complexite ´ que
lorsqu’on a e ´tabli une re `gle les concernant, il faut toujours s’attendre a `
des exceptions plus ou moins nombreuses. [Biological phenomena are so
complex, that when a new rule has been established, it is expected to
ﬁnd several exceptions.]’’ —Elie Metchnikov [1]
U
ntil recently, immunologists had thought of the
immune system as a complex cellular web aimed at
protecting the body against marauding microbes, by
producing a highly specialized, speciﬁc, and adaptive
response. This adaptive response involves the production of a
speciﬁc receptor for each antigenic motif (e.g., B cell
receptors, antibodies, and T cell receptors), using speciﬁc
mechanisms of recombination and rearrangements of
somatic genes. Inherent molecular complexity of the
mechanisms supporting the regulated production of such
receptors monopolized the attention of most immunologists
for several decades. In the late 80s, Janeway explored the
‘‘road not taken’’ and reversed the previous dogma of
adaptive immunity supremacy, stressing a more prominent
role for innate immunity (a ﬁrst line of defense based on the
recognition of conserved pathogen motifs) [2]. In a seminal
paper, he was the ﬁrst to imagine new rules for the immune
system to account for ‘‘the immunologist’s dirty little secret,’’
which had downplayed the need for bacterially derived
adjuvants to efﬁciently induce adaptive immune responses
[3]. Janeway proposed that the immune system recognizes a
conserved molecular pattern, called pathogen-associated
molecular pattern (PAMP), displayed by pathogens but not
normally found on host cells (e.g., lipopolysaccharide,
peptidoglycans, nonmethylated CpG, and double-stranded
RNA). He predicted ‘‘nonclonally distributed’’ (e.g., germline
encoded) receptors for PAMP, and coined the term ‘‘pattern
recognition receptors’’ (PRRs), which he identiﬁed a ﬁrst type
in 1997 as the Toll-like receptors (TLRs) [4]. The discovery of
the TLRs led to the emergence of a revolutionary and fertile
ﬁeld now studied by many. Finally, Janeway proposed that the
innate immune system distinguished ‘‘infectious nonself’’
from ‘‘noninfectious self’’ [5,6]. The infectious nonself (INS)
model revolutionized immunology, although it left several
important questions unanswered. For example, why do PRRs
not discriminate between nonpathogenic and pathogenic
microbes [6]? This question has been partly answered by
recent data revealing a novel function of TLRs in controlling
intestinal epithelial homeostasis through interactions with
nonpathogenic agents [7], while another effort identiﬁed a
‘‘combinatorial security code’’ by which dendritic cells (DCs)
discriminate between pathogens [8]. A second major question
regarding the INS model concerns activation of the immune
system in nonpathogen-associated situations such as allograft
rejection or autoimmunity. For autoimmunity, recent works
demonstrate a crucial role of TLR activation in at least two
murine models of autoimmune diseases such as type 1
diabetes and lupus [9,10].
In the early 90s, Polly Matzinger proposed the ‘‘danger’’
model as an alternative and comprehensive view of the
immune system, where endogenous danger signals (e.g.,
cytokines) released from infected cells could affect the
function of antigen-presenting cells (APCs) without directly
exposing APCs to PAMPs [11]. The danger model had broader
implications than the INS model, since it could predict the
activation of the immune system in various situations such as
anti-infectious and antitumor immunity, autoimmunity, or
allograft rejection. Experimental data have been raised
subsequently showing that necrotic but not apoptotic cells
trigger the activation of DCs, which represent crucial APCs
coupling innate and adaptive responses [12,13]. The danger
model, however, faced several objections raised by the INS
model. Why did evolution select a complex PRR system if
endogenous danger sensors would be sufﬁcient, and what are
the relevant signals (exogenous or endogenous) for mounting
an efﬁcient immune response? Why should the immune
system be cognizant of tissue damage that doesn’t involve
microbes, and would the immune system be activated to
induce autoreactive responses following major cellular
distress?
Recently, Seong and Matzinger stressed that the semantic
distinction between exogenous and endogenous danger
signals is artiﬁcial, since most PAMP such as
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‘‘healthy’’ pathogens but, instead, are released after
signiﬁcant pathogen stress [14]. PAMP and endogenous
danger signals could each be considered damage signals
released either by the host or by the pathogen. PRR such as
TLR recognize either PAMP or endogenous signals, whereas
at least one danger receptor senses PAMP. To account for
this, Seong and Matzinger proposed a synthetic model based
upon the recognition of damage-associated molecular
pattern (DAMP) by DCs. These damage patterns might be
associated with a hydrophobic molecular region exposed
after stress and subsequently recognized as a universal danger
signal.
Here, we explore the DAMP model through a broader
host–pathogen perspective. We propose that pathogens
encode DAMP-interfering molecules that we suggest could be
termed ‘‘negative signals’’ (NS). These NSs might be molecules
displayed or encoded by a pathogen that are not recognized
as DAMP by PRR, and block or modify the intracellular
signaling downstream of PRRs to induce tolerance. We
identiﬁed two major NS strategies used by microbes to
overcome the host immune system: ﬁrst, interfering directly
with APC’s PRR; or second, triggering apoptosis of
phagocytes that in turn inhibit proximal APCs (Figure 1).
Clearly, pathogens use strategies that impair PRR as well as
danger receptors. We focus here on studies that illustrate the
main mechanisms used by bacteria and viruses to escape host
DAMP recognition.
Pathogen NS Interfering with PRR Signaling
Numerous pathogens negatively regulate DAMP signaling
pathways, thus turning off the immune response [15,16]. As
TLRs play a central role in pathogen recognition and
signaling, and many downstream elements of the
transduction cascade are now identiﬁed [17,18], we have
conﬁned our analysis to pathogen-interfering effects on TLR
signaling.
The TLR pathway induces interferon (IFN) production
through several signaling proteins that ultimately lead to the
activation of the transcription factors NF-jB, IFN-regulatory
factor (IRF)3, and IRF7. Viruses possess myriad strategies to
disrupt the TLR cascade, mainly focusing on the IFN
response, while bacteria tend to act further downstream on
mitogen-activated protein kinases (MAPK), mitogen-activated
kinase kinases, and NF-jB [15,16,19,20]. Viruses, indeed, have
to block the IFN response that crucially depends on IRFs, and
the connection between TLR and IRF involves the adaptor
proteins immediately downstream of TLRs [21–23]. Vaccinia
virus (VV) possesses the greatest diversity of NS strategies for
interacting with TLR pathways. The VV A46R protein, a
homolog of Toll-like-interleukin-1 receptor (TIR), targets the
host TIR adaptors MyD88, as well as the MyD88-adaptor-like
TIR-domain-containing adaptor-inducing IFN-b (TRIF), and
TRIF-related adaptor molecule, thereby interfering with
downstream activation of MAPKs, NF-jB, and IRF3 [24,25].
A52R VV protein is a nonredundant effector that associates
with TNF-receptor-associated factor 6 and interleukin-1-
associated kinase 2, blocking the activation of NF-jB [26]. VV
further encodes N1L, a protein that associates with I-jB
kinase complex and TRAF-family-member-associated NF-jB
activator-binding kinase-1 for inhibition. As a result, N1L
disrupts NF-jB signaling and IRF3 signaling pathways. VV
also encodes E3L that inhibits IRF3 and IRF7
phosphorylation through direct interactions [27,28].
Despite high NS variety, bacteria act essentially on MAPK
and NF-jB [15,16]. For example, Bacillus anthracis lethal factor
(LF) is a zinc-dependent metalloprotease that cleaves six of
the seven mitogen-activated kinase kinases [29], as well as
impairs IRF3 [30]. As a result, we and others have shown that
LF disrupts innate and adaptive immunity through DC
impairment [31,32]. Yersinia pestis YopJ and Y. enterocolitica
YopP effector proteins of the type III secretion system target
MAPK signaling pathways and NF-jB [33]. Interestingly, YopJ
and YopP belong to a group of effectors produced by other
pathogens such as Salmonella (AvrA) [34].
Pathogens Exploit the Anti-Inflammatory Properties
of Apoptosis
Surprisingly, numerous pathogens take care to induce a
silent death of host-infected cells via apoptosis [35],
suggesting that this pathway confers an evolutionary
advantage to the pathogen. For viruses, in particular, survival
is highly dependent on their ability to take rapid control of
the host cell cycle, and most of their NS strategies are based
upon regulating apoptosis [36]. Here, we have conﬁned our
analysis to the mechanisms of apoptosis that are speciﬁcally
regulated by pathogens in APCs (macrophages and DCs).
Viruses have developed an extensive molecular repertoire
designed to disrupt DC survival, as these APCs are one of the
ﬁrst lines of cellular defense [37]. Not surprisingly, VV
induces programmed cell death among macrophages and
DCs, although the speciﬁc viral NSs remain to be
characterized [38,39]. Numerous bacterial pathogens also
inﬂuence apoptosis of APCs. B. anthracis induces the
Figure 1. Pathogens Improve Their Survival by Overcoming INS Immune Defenses When Targeting TLRs or ‘‘Danger’’ Immune Defenses When
Targeting Apoptosis
Microbes undertake two major strategies to overcome the host immune system: interfering directly with APC’s pattern recognition receptors (INS
model side), or triggering apoptosis of phagocytes that in turn inhibits proximal APCs (danger model side). Both strategies ultimately lead to tolerance
by inducing presentation of antigen in absence of crucial co-stimulatory molecules.
Viruses have been shown to have a myriad of strategies to disrupt the TLR cascade, mainly focusing on the IFN response, while bacteria act far
downstream on mitogen-activated kinase kinases and NF-jB.
Pathogen-induced cell death induces the release of cellular blebs expressing phosphatidylserine (PS) that are rapidly internalized by neighboring
cells or phagocytes. Infected, apoptotic cells may send these NSs to limit the effectiveness of antigen presentation by neighboring uninfected APCs to T
helper cells. In this situation, without co-stimulatory molecules and secreted IL-12 but in presence of IL-10 and transforming growth factor b, ultimately
tolerance to microbial antigens will be induced.
AP1, activator protein 1; GC-BP, GC binding protein; IFN, interferon; IL, interleukin; IRAK, interleukin-1-associated kinase; IRF, IFN-regulatory factor;
MAPK, mitogen-activated protein kinase; MHC, major histocompatibility complex; MKK, MAPK kinase; MyD88, myeloid differentiation primary-response
factor 88; NF-jB, nuclear factor jB; PSR, phosphatidylserine receptor; TAK, TGF-b-activated kinase; TBK, TRAF-family-member-associated NF-jB activator-
binding kinase; TCR, T cell receptor; TGF, transforming growth factor; TLR, Toll-like receptor; TRAF, TNF-receptor-associated factor; TRAM, TRIF-related
adaptator molecule; TRIF, TIR-domain-containing adaptor inducing IFN-b
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dependent inhibition of p38 [40,41]. Yersinia spp. have at least
two ways to induce macrophage apoptosis: ﬁrst, using TLR2
and TLR4 signaling, and involving TRIF [42]; and second, by
triggering the apoptosis of macrophages through the type III
secretion system effector proteins YopP and YopJ [43–45].
Besides the direct inhibitory effects of YopP and YopJ on
MAPK and NF-jB pathways disrupting the transcription of
antiapoptotic genes, it has been demonstrated that YopP
speciﬁcally triggers the apoptotic pathways above tBid [46].
Viruses have indeed developed many capabilities to silently
kill APCs and to rescue other cell types from programmed
cell death. What consequences might this have for the host?
Besides the direct removal of DCs as potent
immunostimulatory cells, APC apoptosis represents a
supplemental manner to attenuate the immune response [47].
One of the main features of apoptosis is that cytoplasmic
contents are not spilled into the extracellular milieu, and that
apoptotic bodies expressing phosphatidylserine blebs from
apoptotic cells are rapidly internalized by neighboring cells
or phagocytes. The rapid engulfment of apoptotic cells and
apoptotic bodies by neighboring APCs prevents the release of
potentially toxic or immunogenic intracellular contents from
the dying cells. Moreover, apoptotic cells deliver active anti-
inﬂammatory and other inhibitory signals to DCs such as IL-
10 and transforming growth factor b [48–50]. A recent study
further demonstrated that apoptotic cells inhibit IL-12p70
secretion by a phosphatidylserine-driven mechanism [51].
The signals delivered by apoptotic cells to the immune system
have been recently invoked as a means to maintain peripheral
tolerance under a steady state [52]. Further, apoptotic cells as
a source of antigens for cross-presentation have indeed been
shown to play an important role in maintaining peripheral
tolerance in several models [53,54].
Here, we propose that during infections, control of DC
apoptosis is hijacked by pathogens to ‘‘turn down’’ the
immune response. Apoptotic blebs may constitute ‘‘negative
bullets,’’ transmitting both NS and pathogen antigens,
inhibiting the recruitment and activation of proximal APCs,
and ultimately inducing tolerance. It makes biological sense
that pathogens would amplify their immunosuppressive
effects in this manner, since one infected apoptotic cell
releasing a bulk of blebs may impair numerous APCs in the
microenvironment. As a paradigm, measles virus triggers DC
apoptosis and causes severe immunosuppression [55]. The
triggering of APC apoptosis by pathogens could then be
regarded as an efﬁcient weapon of immune silencing. This
alternative strategy may represent a potent NS for danger
signals, just as efﬁcient as NSs that disrupt TLR signaling
directly.
The long history of host–pathogen coevolutionary
interactions has led pathogens to develop efﬁcient tools for
impairing the host immune system. Immunologists have
much to learn from these pathogen strategies, which could
help us to imagine and design new potent tools to control the
immune response in various immunopathological conditions
such as diabetes and related autoimmune diseases, graft
rejection, or allergy. Pathogens, on the other hand, have
evolved under a selective immune pressure that allows them
to thrive whether or not they comprehend immunologist’s
models. “
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